Quantbot Technologies LP Increases Stock Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Quantbot Technologies LP boosted its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 230.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 72,351 shares of the life sciences company’s stock after buying an additional 50,459 shares during the period. Quantbot Technologies LP owned approximately 0.09% of Integra LifeSciences worth $1,315,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Blue Trust Inc. lifted its holdings in shares of Integra LifeSciences by 100.5% in the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock worth $26,000 after buying an additional 444 shares in the last quarter. CWM LLC lifted its stake in Integra LifeSciences by 50.8% in the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock worth $37,000 after purchasing an additional 425 shares in the last quarter. KBC Group NV boosted its holdings in Integra LifeSciences by 65.2% in the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock valued at $52,000 after purchasing an additional 1,120 shares during the period. Northwest Investment Counselors LLC bought a new position in Integra LifeSciences in the 3rd quarter valued at $73,000. Finally, Canada Pension Plan Investment Board bought a new position in shares of Integra LifeSciences in the second quarter worth $114,000. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Trading Up 0.2 %

IART stock opened at $24.58 on Friday. The company has a market capitalization of $1.90 billion, a PE ratio of -273.08, a price-to-earnings-growth ratio of 0.83 and a beta of 1.08. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. Integra LifeSciences Holdings Co. has a one year low of $16.81 and a one year high of $45.42. The company’s 50 day moving average price is $20.77 and its two-hundred day moving average price is $24.00.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $380.80 million for the quarter, compared to analysts’ expectations of $375.81 million. During the same quarter last year, the company earned $0.76 EPS. The firm’s revenue was down .4% compared to the same quarter last year. As a group, analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IART has been the subject of several research analyst reports. Citigroup lifted their price objective on Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research note on Tuesday, November 5th. BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Bank of America decreased their price objective on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a research report on Monday, October 7th. Finally, Truist Financial dropped their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research report on Monday, October 14th. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $24.00.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.